Opportunities

New technology offer: highly selective, orally bioavailable FAP inhibitors

Technology offer: New lead compounds for dry eye disease and validated dry eye disease rat model

Technology offer: Validated gastrointestinal model of visceral pain for preclinical drug testing

Technology offer: New serine protease inhibitors to treat visceral pain for preclinical drug testing